Since the latest expert consensus for FD patients states that renoprotective therapies such as ARB and Sodium-glucose transport protein 2 (SGLT2) inhibitors may be effective (22), administration of SGLT2 inhibitors may also be considered in this case. This evidence concerns the gene SLC5A2 and Fabry disease.